2026 Annual Meeting | SP3 - Society Spotlight: American Society for Gene and Cell Therapy
| 03:30 PM - 03:50 PM CDT | Speaker |
Computational Modeling and Preclinical Evidence Supporting LTS-201, an MSH3-Lowering Therapy for Huntington’s Disease
Bryan Simpson, PhD |
| 03:50 PM - 04:10 PM CDT | Speaker |
Molecular and Behavioral Rescue Following Dual AAV Targeted CRISPR Epigenome Editing in CDKL5 Deficiency Disorder Patient-derived Organoids and Transgenic Mice
Julian Halmai, PhD, MSc |
| 04:10 PM - 04:30 PM CDT | Speaker |
Investigator-initiated Development Paths for Oligonucleotide and Epigenetic Therapies in Prion Disease
Sonia M. Vallabh, PhD |
| 04:30 PM - 04:50 PM CDT | Speaker |
A Next-generation TfR1-binding AAV for Low Dose Systemically Administered CNS Gene Therapies
Benjamin Deverman, PhD |
| 04:50 PM - 05:10 PM CDT | Speaker |
Four Year Follow-up of AAV-mediated Gene Replacement Therapy in a Large Animal Model of Krabbe Disease
Allison M. Bradbury, PhD |
| 05:10 PM - 05:30 PM CDT | Speaker |
Widespread CNS Delivery with Best-in-class Liver Detargeting Following Intravenous Injection of a Novel AAV
Mugdha Deshpande, PhD |
| Steven Gray, PhD | No disclosure on file |
| Sonia M. Vallabh, PhD | An immediate family member of Dr. Vallabh has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Deerfield. Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. An immediate family member of Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. An immediate family member of Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. An immediate family member of Dr. Vallabh has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly & Co.. An immediate family member of Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vertex. An immediate family member of Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Voyager Theapeutics. Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly & Co.. Dr. Vallabh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Voyager Therapeutics. The institution of Dr. Vallabh has received research support from Eli Lilly & Co.. The institution of Dr. Vallabh has received research support from Gate Bioscience. The institution of Dr. Vallabh has received research support from Ionis Pharmaceuticals. The institution of Dr. Vallabh has received research support from Sangamo. Dr. Vallabh has a non-compensated relationship as a President with Prion Alliance that is relevant to AAN interests or activities. |
| Bryan Simpson, PhD | Dr. Simpson has received personal compensation for serving as an employee of Latus Bio. Dr. Simpson has or had stock in Latus Bio. |
| Julian Halmai, PhD, MSc | Dr. Halmai has nothing to disclose. |
| Benjamin Deverman, PhD | Dr. Deverman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Multiple companies and academic institutions. Dr. Deverman has or had stock in Apertura Gene Therapy.Dr. Deverman has or had stock in Tevard Biosciences. The institution of Dr. Deverman has received research support from Apertura Gene Therapy. Dr. Deverman has received intellectual property interests from a discovery or technology relating to health care. Dr. Deverman has received intellectual property interests from a discovery or technology relating to health care. |
| Allison M. Bradbury, PhD | Dr. Bradbury has received intellectual property interests from a discovery or technology relating to health care. |
| Mugdha Deshpande, PhD | Dr. Deshpande has received personal compensation for serving as an employee of Dyno Therapeutics. |
| Peter K. Todd, MD, PhD, FAAN | Dr. Todd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for REATA Therapeutics. Dr. Todd has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Legal services. Dr. Todd has or had stock in Denali Therapeutics. The institution of Dr. Todd has received research support from NIH. The institution of Dr. Todd has received research support from VA. The institution of Dr. Todd has received research support from Ann Arbor Against ALS. The institution of Dr. Todd has received research support from Packard Foudation. Dr. Todd has received intellectual property interests from a discovery or technology relating to health care. Dr. Todd has received publishing royalties from a publication relating to health care. Dr. Todd has received personal compensation in the range of $500-$4,999 for serving as a ANA Highlights module director with American Neurological Association. |